Oxurion NV (OXUR) - Total Liabilities
Based on the latest financial reports, Oxurion NV (OXUR) has total liabilities worth €16.98 Million EUR (≈ $19.85 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore OXUR net assets growth trend to track the company's year-over-year net asset growth rate.
Oxurion NV - Total Liabilities Trend (2006–2024)
This chart illustrates how Oxurion NV's total liabilities have evolved over time, based on quarterly financial data. See OXUR cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Oxurion NV Competitors by Total Liabilities
The table below lists competitors of Oxurion NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PCI Biotech Holding ASA
OL:PCIB
|
Norway | Nkr6.01 Million |
|
Sino-German United AG
F:SGU
|
Germany | €1.03 Million |
|
Virpax Pharmaceuticals Inc
NASDAQ:VRPX
|
USA | $2.47 Million |
|
Baltic Bridge S.A.
WAR:WIS
|
Poland | zł6.36 Million |
|
Rajvir Industries Limited
NSE:RAJVIR
|
India | Rs1.13 Billion |
|
Water Ways Technologies Inc
V:WWT
|
Canada | CA$5.93 Million |
|
VATIC VENTURES CORP.
F:V8V
|
Germany | €1.69 Million |
|
Alchimie Sa
PA:ALCHI
|
France | €15.31 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Oxurion NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Oxurion NV market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oxurion NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oxurion NV (2006–2024)
The table below shows the annual total liabilities of Oxurion NV from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €16.75 Million ≈ $19.59 Million |
-15.11% |
| 2023-12-31 | €19.74 Million ≈ $23.07 Million |
+19.06% |
| 2022-12-31 | €16.58 Million ≈ $19.38 Million |
-17.05% |
| 2021-12-31 | €19.98 Million ≈ $23.36 Million |
+116.37% |
| 2020-12-31 | €9.24 Million ≈ $10.80 Million |
-21.22% |
| 2019-12-31 | €11.72 Million ≈ $13.71 Million |
+22.71% |
| 2018-12-31 | €9.55 Million ≈ $11.17 Million |
-44.06% |
| 2017-12-31 | €17.08 Million ≈ $19.97 Million |
+45.03% |
| 2016-12-31 | €11.78 Million ≈ $13.77 Million |
+31.87% |
| 2015-12-31 | €8.93 Million ≈ $10.44 Million |
-29.69% |
| 2014-12-31 | €12.70 Million ≈ $14.85 Million |
+2.58% |
| 2013-12-31 | €12.38 Million ≈ $14.48 Million |
+10.50% |
| 2012-12-31 | €11.21 Million ≈ $13.10 Million |
+1.31% |
| 2011-12-31 | €11.06 Million ≈ $12.93 Million |
+132.99% |
| 2010-12-31 | €4.75 Million ≈ $5.55 Million |
-36.72% |
| 2009-12-31 | €7.50 Million ≈ $8.77 Million |
+55.95% |
| 2008-12-31 | €4.81 Million ≈ $5.62 Million |
+35.04% |
| 2007-12-31 | €3.56 Million ≈ $4.16 Million |
+73.25% |
| 2006-12-31 | €2.06 Million ≈ $2.40 Million |
-- |
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more